Literature DB >> 27943100

K-Ras, H-Ras, N-Ras and B-Raf mutation and expression analysis in Wilms tumors: association with tumor growth.

Efterpi Dalpa1, Victor Gourvas1, Nikolaos Soulitzis1, Demetrios A Spandidos2.   

Abstract

Nephroblastoma (Wilms tumor) is a kidney neoplasia, predominately occurring at very young age, resulting from the malignant transformation of renal stem cells. The Ras proto-oncogenes and B-Raf are members of an intracellular cascade pathway, which regulates cell growth and differentiation, and ultimately cancer development. Our objective was to determine the mutation rate and to measure the mRNA levels of the three Ras genes and of B-Raf in formalin-fixed paraffin-embedded tissue samples from 32 patients with nephroblastoma and 10 controls. No mutations were detected in the four studied genes among our Wilms tumors cases, while Ras and B-Raf expression was higher in malignant samples versus controls. Statistical analysis revealed a positive correlation of K-Ras (p < 0.001) and B-Raf (p = 0.006) with tumor size, a negative correlation of K-Ras (p = 0.041) and H-Ras (p = 0.033) with the percentage of tissue necrosis, and an association of N-Ras (p = 0.047) and B-Raf (p = 0.044) with tissue histology. From the above, we deduce that although Ras and B-Raf mutations are rare events in Wilms tumors, their expression pattern suggests that they play an important role in the development and progression of this malignancy.

Entities:  

Keywords:  Biomarkers; Nephroblastoma; Oncogenes; RFLP; qPCR

Mesh:

Substances:

Year:  2016        PMID: 27943100     DOI: 10.1007/s12032-016-0862-5

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  64 in total

Review 1.  Guilty as charged: B-RAF is a human oncogene.

Authors:  Mathew J Garnett; Richard Marais
Journal:  Cancer Cell       Date:  2004-10       Impact factor: 31.743

Review 2.  Mitogen-activated protein kinase pathways.

Authors:  M J Robinson; M H Cobb
Journal:  Curr Opin Cell Biol       Date:  1997-04       Impact factor: 8.382

3.  Wilms' tumor in patients with 9q22.3 microdeletion syndrome suggests a role for PTCH1 in nephroblastomas.

Authors:  Bertrand Isidor; Franck Bourdeaut; Delfine Lafon; Ghislaine Plessis; Elodie Lacaze; Caroline Kannengiesser; Sylvie Rossignol; Olivier Pichon; Annaig Briand; Dominique Martin-Coignard; Maria Piccione; Albert David; Olivier Delattre; Cécile Jeanpierre; Nicolas Sévenet; Cédric Le Caignec
Journal:  Eur J Hum Genet       Date:  2012-11-21       Impact factor: 4.246

4.  Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms' tumor.

Authors:  D H Rowe; J Huang; M L Kayton; R Thompson; A Troxel; K M O'Toole; D Yamashiro; C J Stolar; J J Kandel
Journal:  J Pediatr Surg       Date:  2000-01       Impact factor: 2.545

5.  Inhibition of Wilms' tumor growth by intramuscular administration of tissue inhibitor of metalloproteinases-4 plasmid DNA.

Authors:  M Y Celiker; M Wang; E Atsidaftos; X Liu; Y E Liu; Y Jiang; E Valderrama; I D Goldberg; Y E Shi
Journal:  Oncogene       Date:  2001-07-19       Impact factor: 9.867

6.  BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage.

Authors:  Victoria J Mar; Stephen Q Wong; Jason Li; Richard A Scolyer; Catriona McLean; Anthony T Papenfuss; Richard W Tothill; Hojabr Kakavand; Graham J Mann; John F Thompson; Andreas Behren; Jonathan S Cebon; Rory Wolfe; John W Kelly; Alexander Dobrovic; Grant A McArthur
Journal:  Clin Cancer Res       Date:  2013-07-05       Impact factor: 12.531

7.  Transcriptional activation of H-ras, K-ras and N-ras proto-oncogenes in human bladder tumors.

Authors:  D Vageli; H Kiaris; D Delakas; P Anezinis; A Cranidis; D A Spandidos
Journal:  Cancer Lett       Date:  1996-10-22       Impact factor: 8.679

8.  Overexpression of basic fibroblast growth factor complementary DNA in Ha-ras-transformed cells correlates with a decreased incidence of tumor necrosis.

Authors:  D Peretz; N Kimel; D K Fujii; G Neufeld
Journal:  Cancer Res       Date:  1993-01-01       Impact factor: 12.701

9.  Human epidermal growth factor receptor signaling contributes to tumor growth via angiogenesis in her2/neu-expressing experimental Wilms' tumor.

Authors:  Akiko Yokoi; Kimberly W McCrudden; Jianzhong Huang; Eugene S Kim; Samuel Z Soffer; Jason S Frischer; Anna Serur; Tamara New; Jenny Yuan; Mahesh Mansukhani; Kathleen O'toole; Darrell J Yamashiro; Jessica J Kandel
Journal:  J Pediatr Surg       Date:  2003-11       Impact factor: 2.545

10.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

View more
  4 in total

1.  Differential expression profiling of onco and tumor-suppressor genes from major-signaling pathways in Wilms' tumor.

Authors:  Dinesh Kumar Sahu; Neetu Singh; Mumani Das; Jiledar Rawat; Devendra Kumar Gupta
Journal:  Pediatr Surg Int       Date:  2022-09-15       Impact factor: 2.003

2.  Association of KRAS and NRAS gene polymorphisms with Wilms tumor risk: a four-center case-control study.

Authors:  Wen Fu; Zhenjian Zhuo; Rui-Xi Hua; Kai Fu; Wei Jia; Jinhong Zhu; Jiao Zhang; Jiwen Cheng; Haixia Zhou; Huimin Xia; Jing He; Guochang Liu
Journal:  Aging (Albany NY)       Date:  2019-03-12       Impact factor: 5.682

3.  BRAF V600E-mutated metastatic pediatric Wilms tumor with complete response to targeted RAF/MEK inhibition.

Authors:  Patience Obasaju; Shubin Shahab; Emily Dunn; Daniel S Rhee; LiQun Jiang; Jeffrey S Dome; Alan D Friedman; Pedram Argani; Christine A Pratilas
Journal:  Cold Spring Harb Mol Case Stud       Date:  2020-04-01

4.  MicroRNA‑202 inhibits endometrial stromal cell migration and invasion by suppressing the K‑Ras/Raf1/MEK/ERK signaling pathway.

Authors:  Di Zhang; Ling Wang; Hua-Lei Guo; Zi-Wei Zhang; Chong Wang; Ri-Cheng Chian; Zhi-Fen Zhang
Journal:  Int J Mol Med       Date:  2020-10-09       Impact factor: 4.101

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.